Immunocore Working With EMA On Novel TCR Therapy Filing

 
• By Vibha Sharma

While Immunocore is not giving details of what issues it still needs to address regarding its EU filing for tebentafusp, it said the drug is continuing to undergo an accelerated assessment by the CHMP. 

Cytotoxic T cells search and destroy mutated cancer cells - 3d illustration
Tebentafusp redirects T-cells to kill tumor cells • Source: Alamy

More from Approvals

More from Product Reviews